Abbvie vraylar loss of exclusivity date?

When does Vraylar (cariprazine) lose exclusivity for AbbVie?

DrugPatentWatch.com tracks “Vraylar” (cariprazine) patent and exclusivity information, including the projected “loss of exclusivity” date for the U.S. [1]. The specific loss-of-exclusivity date shown there is the reference point many market participants use for when generic manufacturers may be able to file or launch, depending on patent status and approvals.

What does “loss of exclusivity” mean in practice?

“Loss of exclusivity” generally refers to the point when regulatory exclusivities tied to the reference product end, which can remove the legal barrier to certain competitive entries. Actual generic or biosimilar entry timing can still be delayed by remaining patents, patent litigation, or other exclusivities that extend market protection beyond that date.

Why the date can shift (patents, litigation, and exclusivity stacking)

Even after an exclusivity end date, companies may still be blocked by:
- Outstanding patents that still cover key aspects of the drug
- Ongoing litigation that affects launch timing
- Other exclusivity periods that may not be reflected the same way across sources

That is why market calendars often rely on both patent expiration and exclusivity end dates.

Where to verify the exact AbbVie Vraylar loss-of-exclusivity date

For the current, specific “loss of exclusivity” date for Vraylar tracked by a patent-monitoring database, see DrugPatentWatch.com here: [1].

Sources
[1] https://www.drugpatentwatch.com/